Differential modulation of EAE by α9*- and β2*- nicotinic acetylcholine receptors

Immunology and Cell Biology

Volumn 91, Issue 3, 2013, Pages 195-200

  Simard, Alain R ^a,b   Gan, Yan ^c   St Pierre, Stéphanie ^a   Kousari, Ariana ^c   Patel, Varun ^c   Whiteaker, Paul ^c   Morley, Barbara J ^d   Lukas, Ronald J ^c   Shi, Fu Dong ^c  

^a UNIVERSITÉ DE MONCTON   (Canada)

^b Centre de Formation Mé Dicale du Nouveau Brunswick   (Canada)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

^d BOYS TOWN NATIONAL RESEARCH HOSPITAL   (United States)

Author keywords

autoimmunity; cholinergic anti inflammatory pathway; experimental autoimmune encephalomyelitis; inflammation; multiple sclerosis; nicotinic acetylcholine receptors

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MESSENGER RNA; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA9; NICOTINIC RECEPTOR BETA2; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE DELETION; IMMUNE SYSTEM; KNOCKOUT MOUSE; MACROPHAGE; MICROGLIA; MOUSE; NONHUMAN;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE DELETION; INTERLEUKIN-1BETA; MACROPHAGES; MICE; MICE, KNOCKOUT; MICROGLIA; NICOTINE; NICOTINIC AGONISTS; NITRIC OXIDE SYNTHASE TYPE II; REACTIVE OXYGEN SPECIES; RECEPTORS, NICOTINIC; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 84875228693     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2013.1     Document Type: Article

References (20)

1. Tracey KJ. Reflex control of immunity. Nature RevImmunol 2009; 9: 418-428.
2. Shi FD, Piao WH, Kuo YP, Campagnolo DI, Vollmer TL, Lukas RJ. Nicotinic attenuation of central nervous system inflammation and autoimmunity. J Immunol 2009; 182: 1730-1739.
3. Nizri E, Irony-Tur-Sinai M, Lory O, Orr-Urtreger A, Lavi E, Brenner T. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J Immunol 2009; 183: 6681-6688.
4. Hao J, Simard AR, Turner GH, Wu J, Whiteaker P, Lukas RJ et al. Attenuation of CNS inflammatory responses by nicotine involves alpha7 and non-alpha7 nicotinic receptors. Exp Neurol 2011; 227: 110-119.
5. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003; 421: 384-388.
6. Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J et al. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem2004; 89: 337-343.
7. Sato KZ, Fujii T, Watanabe Y, Yamada S, Ando T, Kazuko F et al. Diversity of mRNA expression for muscarinic acetylcholine receptor subtypes and neuronal nicotinic acetylcholine receptor subunits in human mononuclear leukocytes and leukemic cell lines. Neurosci Lett 1999; 266: 17-20.
8. Matsunaga K, Klein TW, Friedman H, Yamamoto Y. Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to Legionella pneumophila infection by nicotine. J Immunol 2001; 167: 6518-6524.
9. Fujii T, Takada-Takatori Y, Kawashima K. Basic and clinical aspects of non-neuronal acetylcholine: expression of an independent, non-neuronal cholinergic system in lymphocytes and its clinical significance in immunotherapy. J Pharmacol Sci 2008; 106: 186-192.
10. Kawashima K, Yoshikawa K, Fujii YX, Moriwaki Y, Misawa H. Expression and function of genes encoding cholinergic components in murine immune cells. Life Sci 2007; 80: 2314-2319.
11. Lukas RJ, Changeux JP, Le Novere N, Albuquerque EX, Balfour DJ, Berg DK et al. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 1999; 51: 397-401.
12. Verbitsky M, Rothlin CV, Katz E, Elgoyhen AB. Mixed nicotinic-muscarinic properties of the alpha9 nicotinic cholinergic receptor. Neuropharmacology 2000; 39: 2515-2524.
13. Gross S, Gammon ST, Moss BL, Rauch D, Harding J, Heinecke JW et al. Bioluminescence imaging of myeloperoxidase activity in vivo. Nat Med 2009; 15: 455-461.
14. Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005; 11: 328-334.
15. Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 2011; 14: 1142-1149.
16. Ding M, Zhang M, Wong JL, Rogers NE, Ignarro LJ, Voskuhl RR. Antisense knockdown of inducible nitric oxide synthase inhibits induction of experimental autoimmune encephalomyelitis in SJL/J mice. J Immunol 1998; 160: 2560-2564.
17. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-1231.
18. Barrette B, Hebert MA, Filali M, Lafortune K, Vallieres N, Gowing G et al. Requirement of myeloid cells for axon regeneration. J Neurosci 2008; 28: 9363-9376.
19. Morley B, Simmons D. Characterization of nicotinic acetylcholine receptor knockout. Proc Midwinter Res Mtng Am Otolaryngol Assoc 2012; 35: 263.
20. Nikodemova M, Watters JJ. Efficient isolation of live microglia with preserved phenotypes from adult mouse brain. J Neuroinflammation 2012; 9: 147.